人黑色素瘤細(xì)胞Malme-3M

簡要描述：青旗（上海）生物技術(shù)發(fā)展有限公司，總部位于上海浦東新區(qū)，依托本地高校資源，逐步發(fā)展成為以生物技術(shù)為主的研發(fā)、生產(chǎn)、培訓(xùn)為一體的綜合化產(chǎn)業(yè)平臺，在標(biāo)準(zhǔn)化細(xì)胞庫建立及細(xì)胞藥物前端模型方面成果顯著。公司生產(chǎn)經(jīng)營原代細(xì)胞、細(xì)胞系、ELISA試劑盒、感受態(tài)細(xì)胞和HPLC檢測等科研產(chǎn)品與服務(wù)。我們秉承對用戶負(fù)責(zé)的態(tài)度，以對科研的高度嚴(yán)謹(jǐn)，以嚴(yán)格的質(zhì)量控制，為廣大生物醫(yī)學(xué)科研用戶提供更優(yōu)質(zhì)的服務(wù)！

更新時(shí)間：2021-05-25

廠商性質(zhì)：生產(chǎn)廠家

瀏覽次數(shù)：289

留言詢價(jià)聯(lián)系我們

詳情介紹

品牌	其他品牌	貨號	BFN607200871
規(guī)格	T25培養(yǎng)瓶x1 1.5ml凍存管x2	供貨周期	現(xiàn)貨
主要用途	僅供科研	應(yīng)用領(lǐng)域	醫(yī)療衛(wèi)生,生物產(chǎn)業(yè)

細(xì)胞名稱	人黑色素瘤細(xì)胞Malme-3M
貨物編碼	BFN607200871
產(chǎn)品規(guī)格	T25培養(yǎng)瓶x1	1.5ml凍存管x2
細(xì)胞數(shù)量	1x10^6	1x10^6
保存溫度	27℃	-198℃
運(yùn)輸方式	常溫保溫運(yùn)輸	干冰運(yùn)輸
安全等級	1
用途限制	僅供科研用途 2類

培養(yǎng)體系	DMEM高糖培養(yǎng)基+10%FBS+1%三抗
培養(yǎng)溫度	37℃	二氧化碳濃度	5%
簡介	人黑色素瘤細(xì)胞Malme-3M 細(xì)胞取自男性惡性黑色素瘤組織，倍增時(shí)間62h.
注釋	Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: MD Anderson Cell Lines Project. Part of: NCI-60 cancer cell line panel. Part of: TCGA-110-CL cell line panel. From: Memorial Sloan Kettering Cancer Center; New York; USA. Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2009-092. Doubling time: 46.2 hours (NCI-DTP). Omics: Array-based CGH. Omics: CNV analysis. Omics: Deep exome analysis. Omics: Deep proteome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: Fluorescence phenotype profiling. Omics: lncRNA expression profiling. Omics: Metabolome analysis. Omics: Protein expression by reverse-phase protein arrays. Omics: SNP array analysis. Omics: Transcriptome analysis. Misspelling: MELM-3M; In Cosmic 1458963. Misspelling: MALME 37; In PubMed=29492214.
STR信息	Amelogenin X,Y CSF1PO 12 D2S1338 24 D3S1358 14,18 D5S818 11 D7S820 9,12 D8S1179 13 D13S317 8,13 D16S539 9,12 D18S51 14 D19S433 13,14 D21S11 30.2,32.2 FGA 21,22 TH01 8 TPOX 8,9 vWA 15,16
參考文獻(xiàn)	PubMed=3335022 Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48:589-601(1988) PubMed=2041050; DOI=10.1093/jnci/83.11.757 Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K., Vistica D.T., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 83:757-766(1991) PubMed=7999427; DOI=10.1016/0959-8049(94)90188-0 Marshall E.S., Matthews J.H.L., Shaw J.H.F., Nixon J., Tumewu P., Finlay G.J., Holdaway K.M., Baguley B.C. Radiosensitivity of new and established human melanoma cell lines: comparison of [3H]thymidine incorporation and soft agar clonogenic assays. Eur. J. Cancer 30:1370-1376(1994) PubMed=10700174; DOI=10.1038/73432 Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V., Jeffrey S.S., van de Rijn M., Waltham M., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24:227-235(2000) PubMed=12068308; DOI=10.1038/nature00766 Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 417:949-954(2002) PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x Tsao H., Goel V., Wu H., Yang G., Haluska F.G. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J. Invest. Dermatol. 122:337-341(2004) PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433 Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol. Cancer Ther. 5:2606-2612(2006) PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921 Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N. DNA fingerprinting of the NCI-60 cell line panel. Mol. Cancer Ther. 8:713-724(2009) PubMed=20164919; DOI=10.1038/nature08768 Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R. Signatures of mutation and selection in the cancer genome. Nature 463:893-898(2010) PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458 Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 70:2158-2164(2010)

驗(yàn)收細(xì)胞注意事項(xiàng)

1、收到人黑色素瘤細(xì)胞Malme-3M 細(xì)胞，請查看瓶子是否有破裂，培養(yǎng)基是否漏出，是否渾濁，如有請盡快聯(lián)系。

2、收到人黑色素瘤細(xì)胞Malme-3M 細(xì)胞，如包裝完好，請?jiān)陲@微鏡下觀察細(xì)胞。,由于運(yùn)輸過程中的問題，細(xì)胞培養(yǎng)瓶中的貼壁細(xì)胞有可能從瓶壁中脫落下來，顯微鏡下觀察會出現(xiàn)細(xì)胞懸浮的情況，出現(xiàn)此狀態(tài)時(shí)，請不要打開細(xì)胞培養(yǎng)瓶，應(yīng)立即將培養(yǎng)瓶置于細(xì)胞培養(yǎng)箱里靜止 3-5 小時(shí)左右，讓細(xì)胞先穩(wěn)定下，再于顯微鏡下觀察，此時(shí)多數(shù)細(xì)胞會重新貼附于瓶壁。如細(xì)胞仍不能貼壁，請用臺盼藍(lán)染色法鑒定細(xì)胞活力，如臺盼藍(lán)染色證實(shí)細(xì)胞活力正常請按懸浮細(xì)胞的方法處理。

3、收到人黑色素瘤細(xì)胞Malme-3M 細(xì)胞后，請鏡下觀察細(xì)胞，用恰當(dāng)方式處理細(xì)胞。若懸浮的細(xì)胞較多，請離心收集細(xì)胞，接種到一個新的培養(yǎng)瓶中。棄掉原液，使用新鮮配制的培養(yǎng)基，使用進(jìn)口胎牛血清。剛接到細(xì)胞，若細(xì)胞不多時(shí) 血清濃度可以加到 15％去培養(yǎng)。若細(xì)胞迏到 80%左右，血清濃度還是在 10％。

4、收到人黑色素瘤細(xì)胞Malme-3M 細(xì)胞時(shí)如無異常情況，請?jiān)陲@微鏡下觀察細(xì)胞密度，如為貼壁細(xì)胞，未超過80%匯合度時(shí)，將培養(yǎng)瓶中培養(yǎng)基吸出，留下 5-10ML 培養(yǎng)基繼續(xù)培養(yǎng)：超過 80%匯合度時(shí)，請按細(xì)胞培養(yǎng)條件傳代培養(yǎng)。如為懸浮細(xì)胞，吸出培養(yǎng)液，1000 轉(zhuǎn)/分鐘離心 3 分鐘，吸出上清，管底細(xì)胞用新鮮培養(yǎng)基懸浮細(xì)胞后移回培養(yǎng)瓶。

5、將培養(yǎng)瓶置于 37℃培養(yǎng)箱中培養(yǎng)，蓋子微微擰松。吸出的培養(yǎng)基可以保存在滅菌過的瓶子里，存放于 4℃冰箱，以備不時(shí)之需。

6、24 小時(shí)后，細(xì)胞形態(tài)已恢復(fù)并貼滿瓶壁，即可傳代。（貼壁細(xì)胞）將培養(yǎng)瓶里的培養(yǎng)基倒去，加 3-5ml（以能覆蓋細(xì)胞生長面為準(zhǔn)）PBS 或 Hanks’液洗滌后棄去。加 0.5-1ml 0.25%含 EDTA 的胰酶消化，消化時(shí)間以具體細(xì)胞為準(zhǔn)，一般 1-3 分鐘，不超過 5 分鐘?？梢苑?/span>入37℃培養(yǎng)箱消化。輕輕晃動瓶壁，見細(xì)胞脫落下來，加入 3-5ml 培養(yǎng)基終止消化。用移液管輕輕吹打瓶壁上的細(xì)胞，使之*脫落，然后將溶液吸入離心管內(nèi)離心，1000rpm/5min。棄上清，視細(xì)胞數(shù)量決定分瓶數(shù)，一般一傳二，如細(xì)胞量多可一傳三，有些細(xì)胞不易傳得過稀，有些生長較快的細(xì)胞則可以多傳幾瓶，以具體細(xì)胞和經(jīng)驗(yàn)為準(zhǔn)。（懸浮細(xì)胞）用移液管輕輕吹打瓶壁，直接將溶液吸入離心管離心即可。